書籍詳細

索引・図表・文献

P.169 掲載の参考文献

• 1) 山下武志. Old and New 心房細動の抗凝固療法. メディカルサイエンス社, 東京, 2012.

• 2) イグザレルト(R)錠 インタビューフォーム, 2012年10月. バイエル薬品株式会社.

• 3) Mueck W, et al. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor-in healthy subjects. Int J Clin Pharmacol Ther. 2007 Jun ; 45(6) : 335-344.
  pubmed

• 4) Tanigawa T, et al. Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation. Drug Metab Pharmacokinet. 2013 ; 28(1) : 59-70.
  pubmed

• 5) Mueck W, et al. Co-administration of rivaroxaban with drugs that share its elimination pathways : pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013 Sep ; 76(3) : 455-466.
  pubmed

• 6) Samama MM, et al. Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost. 2010 Apr ; 103(4) : 815-825.
  pubmed

• 7) The ROCKET AF Trial (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). FDA Draft Briefing Document for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC). 8 September 2011, 202439.

• 8) Patel MR, et al. ; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8 ; 365(10) : 883-891.

• 9) Supplementary Appendix to : Patel MR, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.N Engl J Med 2011. DOI : 10. 1056/NEJMoa1009638.

• 10) Patel MR, et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation : analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). J Am Coll Cardiol. 2013 Feb 12 ; 61(6) :651-658.

• 11) Hori M, et al. ; J-ROCKET AF study investigators. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation-the J-ROCKET AF study-. Circ J. 2012 ; 76(9) : 2104-2111.

• 12) Fox KA, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011 Oct ; 32(19) : 2387-2394.

• 13) Hori M, et al. ; J-ROCKET AF study investigators. Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with nonvalvular atrial fibrillation : subanalysis of J-ROCKET AF for patients with moderate renal impairment. Circ J. 2013 ; 77(3) : 632-638.

• 14) イグザレルト(R)錠適正使用ガイド. バイエル薬品株式会社.

• 15) Hori M, et al. ; RE-LY Investigators. Dabigatran versus warfarin : effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke. 2013 Jul ; 44(7) : 1891-1896.
  pubmed

• 16) Agnelli G, et al. ; ODIXa-DVT Study Investigators. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939) : the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation. 2007 Jul 10 ; 116(2) : 180-187.

• 17) Mega JL, et al. ; ATLAS ACS-TIMI 46 study group.Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACSTIMI 46) : a randomised, double-blind, phase II trial. Lancet. 2009 Jul 4 ; 374(9683) : 29-38.

• 18) Zhang D, et al. Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor : administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats. Drug Metab Dispos. 2013 Apr ; 41(4) : 906-915.
  pubmed

• 19) エリキュース(R)錠 インタビューフォーム, 2012年12月. ブリストル・マイヤーズ株式会社.

• 20) Frost C, et al. Apixaban, an oral, direct factor Xa inhibitor : single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. 2013 Feb ; 75(2) : 476-487.
  pubmed

• 21) Upreti VV, et al. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol. 2013 Dec ; 76(6) : 908-916.
  pubmed

• 22) Douxfils J, et al. Impact of apixaban on routine and specific coagulation assays : a practical laboratory guide. Thromb Haemost. 2013 Aug ; 110(2) : 283-294.
  pubmed

• 23) Granger CB, et al. ; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15 ; 365(11) : 981-992.

• 24) Connolly SJ, et al. ; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011 Mar 3 ; 364(9) : 806-817.

• 25) Flaker GC, et al. Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin : the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial. Stroke. 2012 Dec ; 43(12) : 3291-3297.
  pubmed

• 26) Leil TA, et al. Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism : selection of phase III trial dose. Clin Pharmacol Ther. 2010 Sep ; 88(3) : 375-382.
  pubmed

• 27) Lee S, et al. Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom : a cross-sectional analysis using the General Practice Research Database. BMJ Open. 2012 ; Dec 14 ; 2(6) : e001768. doi : 10.1136/bmjopen-2012-001768.

• 28) Hohnloser SH, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation : insights from the ARISTOTLE trial. Eur Heart J. 2012 Nov ; 33(22) : 2821-2830.
  pubmed

• 29) Alexander JH, et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation : insights from the ARISTOTLE trial. Eur Heart J. 2014 Jan ; 35(4) : 224-232.
  pubmed

• 30) Dans AL, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation. 2013 Feb 5 ; 127(5) : 634-640.
  pubmed

• 31) 山下武志, 赤尾昌治. 新規抗凝固薬の適正使用. Pharma Medica. 2013 ; 31(2) : 145-151.
  Medical*Online

• 32) Halvorsen S. et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2013 ; 61(10_S) : .doi : 10.1016/S0735-1097(13)60315-0.

• 33) リクシアナ(R)錠 インタビューフォーム. 2012年9月. 第一三共株式会社.

• 34) Mendell J, et al. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs. 2013 Oct ; 13(5) : 331-342.
  pubmed

• 35) Weitz JI, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010 Sep ; 104(3) : 633-641.
  pubmed

• 36) Wolzt M, et al. Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux. Thromb Haemost. 2011 Jun ; 105(6) : 1080-1090.
  pubmed

• 37) Yamashita T, et al. Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation. Circ J. 2012 ; 76(8) : 1840-1847.
  pubmed

• 38) Weitz JI, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010 Sep ; 104(3) : 633-641.
  pubmed

• 39) Salazar DE, et al. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost. 2012 May ; 107(5) : 925-936.
  pubmed

• 40) Ruff CT, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation : a meta-analysis of randomised trials. Lancet. 2013 Dec 4. pii : S0140-6736(13)62343-0. doi : 10. 1016/S0140-6736(13)62343-0. [Epub ahead of print].

• 41) Giugliano RP, et al. ; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov 28 ; 369(22) : 2093-2104.
  pubmed

• 42) Eikelboom JW, et al. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation. J Am Coll Cardiol. 2013 Sep 3 ; 62(10) : 900-908.

• 43) Eikelboom JW, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation : an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011 May 31 ; 123(21) : 2363-2372.
  pubmed

• 44) Inoue H, et al. ; J-RHYTHM Registry Investigators. Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation : results of the J-RHYTHM Registry. Circ J. 2013 ; 77(9) : 2264-2270.

• 45) 向殿政男/監修, 安全技術応用研究会/編. 国際化時代の機械システム安全技術. 3章 安全技術の国際標準, 3.3 日本と欧米の安全に対する考え方の相違. 日刊工業新聞社, 2000. p.79

• 46) Hijazi Z, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation : a RE-LY trial analysis. Circulation. 2014 Mar 4 ; 129(9) : 961-970.